B-cell lymphoma 2 (BCL-2) family proteins primarily work as a programmed cell death
regulator, whereby multiple interactions between them determine cell survival. This explains …

Rapidly developing molecular biology techniques have been employed to identify cancer
driver genes in specimens from patients with non-small cell lung cancer (NSCLC). Inhibitors …

Introduction Recent studies have identified subtypes of small cell lung carcinoma (SCLC)
defined by the RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1 transcriptional …

Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based …

The outcomes of patients with SCLC have not yet been substantially impacted by the
revolution in precision oncology, primarily owing to a paucity of genetic alterations in …

Although small cell lung cancer (SCLC) is treated as a homogeneous disease, biopsies and
preclinical models reveal heterogeneity in transcriptomes and morphology. SCLC subtypes …

Epigenetic mechanisms comprising DNA methylation, histone modifications, and noncoding
RNAs affect chromatin structure and regulate gene expression. These mechanisms control …

Background Cells have evolved balanced mechanisms to protect themselves by initiating a
specific response to a variety of stress. The TP53 gene, encoding P53 protein, is one of the …

Small-cell lung cancer (SCLC) accounts for 13–15% of all new lung cancer cases in the US.
The tumor has a tendency to disseminate early resulting in 80–85% of patients being …

Small‐cell lung cancer (SCLC) accounts for approximately 15% of lung cancer cases;
however, it is characterized by easy relapse and low survival rate, leading to one of the most …